Academic Journal
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer
| العنوان: | Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer |
|---|---|
| المؤلفون: | Manchanda, Ranjit, Sun, Li, Sobocan, Monika, Rodriguez, Isabel V, Wei, Xia, Kalra, Ashwin, Oxley, Samuel, Sideris, Michail, Fierheller, Caitlin T, Morgan, Robert D, Chandrasekaran, Dhivya, Rust, Kelly, Spiliopoulou, Pavlina, Miller, Rowan E, Crusz, Shanthini M, Lockley, Michelle, Singh, Naveena, Faruqi, Asma, Casey, Laura, Brockbank, Elly, Phadnis, Saurabh, Mills-Baldock, Tina, El-Khouly, Fatima, Jenkins, Lucy A, Wallace, Andrew, Ahmed, Munaza, Kumar, Ajith, Swisher, Elizabeth M, Gourley, Charlie, Norquist, Barbara M, Evans, D Gareth, Legood, Rosa |
| المصدر: | Journal of the National Comprehensive Cancer Network , 22 (2D) , Article e237331. (2024) |
| بيانات النشر: | Jones and Barlett Publishers |
| سنة النشر: | 2024 |
| المجموعة: | University College London: UCL Discovery |
| الوصف: | BACKGROUND: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and allow for precision prevention in unaffected relatives with PVs. In this study, we estimate the cost-effectiveness and population impact of parallel panel germline and somatic BRCA testing of all patients with OC incorporating PARPi therapy in the United Kingdom and the United States compared with clinical criteria/family history (FH)-based germline BRCA testing. We also evaluate the cost-effectiveness of multigene panel germline testing alone. METHODS: Microsimulation cost-effectiveness modeling using data from 2,391 (UK: n=1,483; US: n=908) unselected, population-based patients with OC was used to compare lifetime costs and effects of panel germline and somatic BRCA testing of all OC cases (with PARPi therapy) (strategy A) versus clinical criteria/FH-based germline BRCA testing (strategy B). Unaffected relatives with germline BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 PVs identified through cascade testing underwent appropriate OC and breast cancer (BC) risk-reduction interventions. We also compared the cost-effectiveness of multigene panel germline testing alone (without PARPi therapy) versus strategy B. Unaffected relatives with PVs could undergo risk-reducing interventions. Lifetime horizon with payer/societal perspectives, along with probabilistic/one-way sensitivity analyses, are presented. Incremental cost-effectiveness ratio (ICER) and incremental cost per quality-adjusted life year (QALY) gained were compared with £30,000/QALY (UK) and $100,000/QALY (US) thresholds. OC incidence, BC incidence, and prevented deaths were estimated. RESULTS: Compared with clinical criteria/FH-based BRCA testing, BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 germline testing and BRCA1/BRCA2 somatic testing of all patients with OC incorporating PARPi therapy had a UK ICER of £51,175/QALY (payer perspective) and £50,202/QALY (societal ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| Relation: | https://discovery.ucl.ac.uk/id/eprint/10193786/ |
| الاتاحة: | https://discovery.ucl.ac.uk/id/eprint/10193786/1/Manchanda_Cost-Effectiveness%20of%20Unselected%20Multigene%20Germline%20and%20Somatic%20Genetic%20Testing%20for%20Epithelial%20Ovarian%20Cancer_VoR.pdf https://discovery.ucl.ac.uk/id/eprint/10193786/ |
| Rights: | open |
| رقم الانضمام: | edsbas.AED19029 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |